Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Manpixiao for Chronic Atrophic Gastritis
NCT05493124Phase 1Unknown
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of manpixiao in chronic atrophic gastritis (CAG) (3 arms), sponsored by Beijing University of Chinese Medicine. Primary endpoint: Pathological improvement rate of gastric mucosa at 28 weeks. Status: unknown.
02
Drugs
manpixiao
03
Conditions
chronic atrophic gastritis (CAG)
Beyond the preview
Go deeper on NCT05493124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493124.